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objectives: We examined the effectiveness of the Tandem Heart ventricular assist device (Cardiac Assist Inc., Pittsburgh, PA) in patients with severe 
refractory cardiogenic shock (SRCS).
background:  In-hospital mortality of cardiogenic shock remains high, ranging from 45 to 60%. The TandemHeart is a percutaneously inserted 
ventricular assist device (pVAD) that provides left atrial to femoral artery bypass, with flow rates up to 5L/min. Its safety and effectiveness should be 
further confirmed in patients with SRCS who failed multiple pressors/inotropes and/or intra-aortic balloon support.
Methods:  We reviewed a total of 16 consecutive patients with SRCS that underwent TandemHeart placement at the Michael E. DeBakey Veteran 
Affairs Medical Center (2009-2012). Data were collected on clinical characteristics, biochemical values, hemodynamic measures, and clinical 
outcomes.
results:  Of the 16 patients, 11 (69%) patients had ischemic cardiomyopathy. 5 (31%) patients had cardiovascular collapse and were undergoing 
cardiopulmonary resuscitation. The average duration of support was 8.7 ± 2.7 days. Hemodynamic parameters and biochemical values improved 
after TandemHeart insertion (Table).
Value pre-VAD with VAD p Value
CI (L/min*m^2) 1.8 ± 0.35 3.0 ± 0.29 0.0698
SBP (mmHg) 82.3 ± 5.3 155.6 ± 4.5 < 0.0001
DBP (mmHg) 45.2 ± 3.3 89.1 ± 5.0 < 0.0001
MAP (mmHg) 56.0 ± 3.7 108.2 ± 3.2 < 0.0001
SVO2 (%) 51.0 ± 4.2 83.8 ± 2.8 0.0054
PCWP (mmHg) 33.3 ± 4.8 17.7 ± 2.8 0.0362
PAP (mmHg) 55.4 ± 3.1 16.1 ± 2.2 0.0042
pH 7.24 ± 0.05 7.52 ± 0.03 0.0302
Cr (mg/dL) 2.41 ± 0.38 1.31 ± 0.15 0.0028
BUN (mg/dL) 46.0 ± 8.4 25.4 ± 3.2 0.0037
Urine output (mL/hr) 34.0 ± 7.9 277.8 ± 42.6 < 0.0001
Hemoglobin 10.7 ± 0.62 12.6 ± 0.48 0.0101
AST 486.7 ± 136.2 120.2 ± 48.6 0.0239
ALT 312.9 ± 117.7 123.8 ± 67.1 0.0645
Thirty-day mortality, six-month, and one-year mortality outcomes were 20%, 47%, and 53%, respectively.
conclusion:  The TandemHeart pVAD provided safe and effective hemodynamic support in patients with SRCS and resulted in lower mortality rates 
compared to the existing literature.
